Intercept Pharmaceuticals (NASDAQ:ICPT)‘s stock had its “market perform” rating reiterated by research analysts at Wells Fargo & Co in a research report issued on Tuesday, The Fly reports. They presently have a $57.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $62.00. Wells Fargo & Co’s target price indicates a potential upside of 1.75% from the company’s previous close.

Several other research analysts have also weighed in on ICPT. Wedbush reiterated a “buy” rating and issued a $253.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, December 22nd. BidaskClub upgraded Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 25th. Leerink Swann restated a “hold” rating and set a $60.00 price target on shares of Intercept Pharmaceuticals in a research report on Tuesday, November 28th. Deutsche Bank assumed coverage on Intercept Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $103.00 price target for the company. Finally, ValuEngine upgraded Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st. Five research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $132.14.

Shares of Intercept Pharmaceuticals (ICPT) traded up $2.61 during trading on Tuesday, reaching $56.02. The company had a trading volume of 1,447,000 shares, compared to its average volume of 1,096,101. The stock has a market capitalization of $1,490.00, a price-to-earnings ratio of -4.24 and a beta of -2.13. Intercept Pharmaceuticals has a 52 week low of $51.05 and a 52 week high of $135.59. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share for the quarter, missing the consensus estimate of ($3.39) by ($1.04). The business had revenue of $37.69 million during the quarter, compared to analysts’ expectations of $39.01 million. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The company’s revenue was up 173.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($4.84) earnings per share. equities research analysts predict that Intercept Pharmaceuticals will post -13.52 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in ICPT. Alliancebernstein L.P. raised its stake in shares of Intercept Pharmaceuticals by 6.2% in the second quarter. Alliancebernstein L.P. now owns 9,459 shares of the biopharmaceutical company’s stock valued at $1,145,000 after acquiring an additional 550 shares in the last quarter. Teachers Advisors LLC raised its stake in shares of Intercept Pharmaceuticals by 16.1% in the second quarter. Teachers Advisors LLC now owns 18,430 shares of the biopharmaceutical company’s stock valued at $2,231,000 after acquiring an additional 2,559 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Intercept Pharmaceuticals by 23.3% in the second quarter. PNC Financial Services Group Inc. now owns 2,490 shares of the biopharmaceutical company’s stock valued at $302,000 after acquiring an additional 470 shares in the last quarter. Northern Trust Corp raised its stake in shares of Intercept Pharmaceuticals by 14.9% in the second quarter. Northern Trust Corp now owns 84,983 shares of the biopharmaceutical company’s stock valued at $10,289,000 after acquiring an additional 10,993 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Intercept Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after acquiring an additional 57,149 shares in the last quarter. Institutional investors and hedge funds own 75.48% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Intercept Pharmaceuticals (ICPT) Receives “Market Perform” Rating from Wells Fargo & Co” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/02/13/intercept-pharmaceuticals-icpt-given-market-perform-rating-at-wells-fargo-co.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

The Fly

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.